{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:00:22Z","timestamp":1794898822821,"version":"4.9.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012308","name":"National Jewish Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.chest.2024.08.037","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:26:01Z","timestamp":1737980761000},"page":"1044-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2052-0102","authenticated-orcid":false,"given":"Paul","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-3711","authenticated-orcid":false,"given":"Yohan","family":"Boss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-9859","authenticated-orcid":false,"given":"Kenneth R.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-4651","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Maltais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-8450","authenticated-orcid":false,"given":"Erika D.","family":"Penz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-0481","authenticated-orcid":false,"given":"Brandie L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-2869","authenticated-orcid":false,"given":"Avtar","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1452","authenticated-orcid":false,"given":"Darcy D.","family":"Marciniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib1","first-page":"81","article-title":"Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society","volume":"8","author":"Abboud","year":"2001","journal-title":"Can Respir J"},{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib2","first-page":"109","article-title":"Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline","volume":"19","author":"Marciniuk","year":"2012","journal-title":"Can Respir J"},{"key":"10.1016\/j.chest.2024.08.037_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/00365516309051324","article-title":"The electrophoretic alpha-globulin pattern of serum in alpha-1-antitrypsin deficiency","volume":"15","author":"Laurell","year":"1963","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00610-2017","article-title":"European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha(1)-antitrypsin deficiency","volume":"50","author":"Miravitlles","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.08.037_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/resp.13774","article-title":"Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: a position statement from the Thoracic Society of Australia and New Zealand","volume":"25","author":"Dummer","year":"2020","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib6","first-page":"841","article-title":"C.T.S. Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency","volume":"146","year":"1992","journal-title":"CMAJ"},{"issue":"7","key":"10.1016\/j.chest.2024.08.037_bib7","first-page":"173","article-title":"2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD","volume":"2023","author":"Bourbeau","year":"2023","journal-title":"Can J Resp Crit Care Sleep Med"},{"key":"10.1016\/j.chest.2024.08.037_bib8","series-title":"Management and Prevention of COPD: 2024 Report. Global Initiative for Chronic Obstructive Lung Disease","year":"2024"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"18","key":"10.1016\/j.chest.2024.08.037_bib11","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/thx.2003.006528","article-title":"Alpha1-antitrypsin deficiency. 4: molecular pathophysiology","volume":"59","author":"Lomas","year":"2004","journal-title":"Thorax"},{"issue":"15","key":"10.1016\/j.chest.2024.08.037_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha(1)-antitrypsin deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-5793(76)80478-4","article-title":"Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ","volume":"65","author":"Jeppsson","year":"1976","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0005-2795(76)90271-3","article-title":"The abnormality of the S variant of human alpha-1-antitrypsin","volume":"453","author":"Owen","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1183\/09031936.05.00021605","article-title":"alpha1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants","volume":"26","author":"Senn","year":"2005","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.rmed.2008.01.009","article-title":"Alpha-1 antitrypsin null mutations and severity of emphysema","volume":"102","author":"Fregonese","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2024.08.037_bib20","series-title":"GeneReviews((R))","article-title":"Aboussouan LS Alpha-1 antitrypsin deficiency","author":"Stoller","year":"1993"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/ajrccm.161.1.9812131","article-title":"Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ","volume":"161","author":"Seersholm","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/15412555.2012.665520","article-title":"Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD","volume":"11","author":"Bourbeau","year":"2014","journal-title":"COPD"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00958-2020","article-title":"Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD","volume":"56","author":"Gupta","year":"2020","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.08.037_bib24","first-page":"668","article-title":"The diagnosis and management of alpha-1 antitrypsin deficiency in the adult","volume":"3","author":"Sandhaus","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01441-2020","article-title":"The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes","volume":"56","author":"Nakanishi","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib26","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1378\/chest.128.4.1989","article-title":"Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem","volume":"128","author":"Stoller","year":"2005","journal-title":"Chest"},{"issue":"9478","key":"10.1016\/j.chest.2024.08.037_bib27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/S0140-6736(05)66781-5","article-title":"Alpha1-antitrypsin deficiency","volume":"365","author":"Stoller","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.chest.2024.08.037_bib28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1164\/rccm.168.7.818","article-title":"American Thoracic Society\/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency","volume":"168","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2024.08.037_bib29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1164\/rccm.200406-761OC","article-title":"Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment","volume":"170","author":"Parr","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"sup1","key":"10.1016\/j.chest.2024.08.037_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/15412555.2013.764404","article-title":"Airway disease in alpha-1 antitrypsin deficiency","volume":"10","author":"Strange","year":"2013","journal-title":"COPD"},{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.chest.2021.09.041","article-title":"Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and health care engagement among direct-to-consumer recipients of a personalized genetic risk report","volume":"161","author":"Ashenhurst","year":"2022","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2024.08.037_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4187\/respcare.06555","article-title":"The impact of delayed diagnosis of alpha-1 antitrypsin deficiency: the association between diagnostic delay and worsened clinical status","volume":"64","author":"Tejwani","year":"2019","journal-title":"Respir Care"},{"key":"10.1016\/j.chest.2024.08.037_bib33","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2147\/COPD.S130925","article-title":"Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry","volume":"12","author":"Bernhard","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12931-023-02338-0","article-title":"The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry","volume":"24","author":"Meischl","year":"2023","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.chest.2024.08.037_bib35","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1373\/clinchem.2006.072991","article-title":"Diagnosis of alpha-1-antitrypsin deficiency: an algorithm of quantification, genotyping, and phenotyping","volume":"52","author":"Snyder","year":"2006","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.trsl.2007.08.001","article-title":"Laboratory diagnosis of alpha1-antitrypsin deficiency","volume":"150","author":"Ferrarotti","year":"2007","journal-title":"Transl Res"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jmoldx.2015.07.002","article-title":"SERPINA1 full-gene sequencing identifies rare mutations not detected in targeted mutation analysis","volume":"17","author":"Graham","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib38","first-page":"464","article-title":"IntraIndividual variability in serum alpha-1 antitrypsin levels","volume":"8","author":"Haillot","year":"2021","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"7","key":"10.1016\/j.chest.2024.08.037_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23279","article-title":"Molecular diagnosis of alpha1-antitrypsin deficiency: a new method based on Luminex technology","volume":"34","author":"Ottaviani","year":"2020","journal-title":"J\u00a0Clin Lab Anal"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib40","first-page":"1154","article-title":"Characterization of the molecular basis of the alpha 1-antitrypsin F allele","volume":"48","author":"Okayama","year":"1991","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1016\/j.chest.2024.08.037_bib41","first-page":"5132","article-title":"Methodologies for the determination of blood alpha1 antitrypsin levels: a systematic review","volume":"10","author":"Ruiz-Duque","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib42","first-page":"31","article-title":"The clinical utility of determining the allelic background of mutations causing alpha-1 antitrypsin deficiency: the case with the null variant Q0(Mattawa)\/Q0(Ourem)","volume":"8","author":"Bellemare","year":"2021","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"17","key":"10.1016\/j.chest.2024.08.037_bib43","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM198704233161704","article-title":"Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema","volume":"316","author":"Wewers","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2024.08.037_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15412550902905961","article-title":"Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis","volume":"6","author":"Chapman","year":"2009","journal-title":"COPD"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib45","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1164\/ajrccm\/140.5.1494","article-title":"Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency","volume":"140","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.chest.2024.08.037_bib46","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1164\/ajrccm.161.3.9906011","article-title":"Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group","volume":"161","author":"Schluchter","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"9991","key":"10.1016\/j.chest.2024.08.037_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.chest.2024.08.037_bib48","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/thorax.58.12.1020","article-title":"Predictors of mortality in alpha1-antitrypsin deficiency","volume":"58","author":"Dawkins","year":"2003","journal-title":"Thorax"},{"issue":"5 Pt 1","key":"10.1016\/j.chest.2024.08.037_bib49","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","article-title":"A\u00a0randomized clinical trial of alpha(1)-antitrypsin augmentation therapy","volume":"160","author":"Dirksen","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib50","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.00159408","article-title":"Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency","volume":"33","author":"Dirksen","year":"2009","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib51","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2019","article-title":"Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD","volume":"54","author":"Stolk","year":"2019","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2024.08.037_bib52","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/bcp.13358","article-title":"Quantitative disease progression model of alpha-1 proteinase inhibitor therapy on computed tomography lung density in patients with alpha-1 antitrypsin deficiency","volume":"83","author":"Tortorici","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.rmed.2015.01.022","article-title":"SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency","volume":"109","author":"Sorrells","year":"2015","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(16)30430-1","article-title":"Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)","volume":"5","author":"McElvaney","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1164\/rccm.202002-0262OC","article-title":"Clarifying the risk of lung disease in SZ alpha-1 antitrypsin deficiency","volume":"202","author":"Franciosi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib56","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1378\/chest.122.5.1818","article-title":"Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys","volume":"122","author":"de Serres","year":"2002","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/thorax.2003.006494","article-title":"Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency","volume":"59","author":"Luisetti","year":"2004","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.chest.2024.08.037_bib58","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1378\/chest.89.3.370","article-title":"Alpha 1-antitrypsin Pi-types in 965 COPD patients","volume":"89","author":"Lieberman","year":"1986","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1164\/ajrccm\/140.4.961","article-title":"Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening","volume":"140","author":"Silverman","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"12","key":"10.1016\/j.chest.2024.08.037_bib60","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2213-2600(19)30141-9","article-title":"Pitfalls and caveats in alpha1-antitrypsin deficiency testing: a guide for clinicians","volume":"7","author":"Franciosi","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/15412555.2017.1401600","article-title":"The effects of inflammation on alpha 1 antitrypsin levels in a national screening cohort","volume":"15","author":"Sanders","year":"2018","journal-title":"COPD"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib62","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1373\/clinchem.2005.062059","article-title":"Validation of a rapid, simple method to measure alpha1-antitrypsin in human dried blood spots","volume":"52","author":"Gorrini","year":"2006","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.chest.2024.08.037_bib63","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.trsl.2010.12.014","article-title":"C\u00a0reactive protein and alpha1-antitrypsin: relationship between levels and gene variants","volume":"157","author":"Ottaviani","year":"2011","journal-title":"Transl Res"},{"issue":"4","key":"10.1016\/j.chest.2024.08.037_bib64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1164\/rccm.201311-1984OC","article-title":"Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes","volume":"189","author":"Molloy","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib65","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.201904-0769OC","article-title":"The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS","volume":"201","author":"Ortega","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2024.08.037_bib66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2021.06.001","article-title":"Alpha1-antitrypsin deficiency: new therapies on the horizon","volume":"59","author":"Remih","year":"2021","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"10.1016\/j.chest.2024.08.037_bib67","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41587-022-01225-1","article-title":"Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides","volume":"40","author":"Monian","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.chest.2024.08.037_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1513\/AnnalsATS.201708-694RL","article-title":"Clinical experience with SERPINA1 DNA sequencing to detect alpha-1 antitrypsin deficiency","volume":"15","author":"Maltais","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"oct18 2","key":"10.1016\/j.chest.2024.08.037_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.chest.2024.08.037_bib70","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.chest.2024.08.037_bib71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13012-015-0225-1","article-title":"The Guideline Implementability Decision Excellence Model (GUIDE-M): a mixed methods approach to create an international resource to advance the practice guideline field","volume":"10","author":"Brouwers","year":"2015","journal-title":"Implement Sci"},{"issue":"5","key":"10.1016\/j.chest.2024.08.037_bib72","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jclinepi.2014.12.013","article-title":"Guideline uptake is influenced by six implementability domains for creating and communicating guidelines: a realist review","volume":"68","author":"Kastner","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"14","key":"10.1016\/j.chest.2024.08.037_bib73","doi-asserted-by":"crossref","first-page":"E362","DOI":"10.1503\/cmaj.151102","article-title":"Optimizing the language and format of guidelines to improve guideline uptake","volume":"188","author":"Gupta","year":"2016","journal-title":"CMAJ"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224051298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224051298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:04:33Z","timestamp":1762124673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224051298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0012369224051298"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.08.037","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Canadian Thoracic Society and American College of Chest Physicians. Published by Taylor and Francis Group, LLC on behalf of Canadian Thoracic Society and by Elsevier Inc. on behalf of American College of Chest Physicians. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}